Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia

• Verfasst von: Jaramillo Segura, Sonia [VerfasserIn]
• Verfasst von: Benner, Axel [VerfasserIn]
• Verfasst von: Schlenk, Richard Friedrich [VerfasserIn]
• Titel: Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia
• Verf.angabe: S. Jaramillo, A. Benner, J. Krauter, H. Martin, T. Kindler, M. Bentz, H. R. Salih, G. Held, C.-H. Köhne, K. Götze, M. Lübbert, A. Kündgen, P. Brossart, M. Wattad, H. Salwender, B. Hertenstein, D. Nachbaur, G. Wulf, H.-A. Horst, H. Kirchen, W. Fiedler, A. Raghavachar, G. Russ, S. Kremers, E. Koller, V. Runde, G. Heil, D. Weber, G. Göhring, K. Döhner, A. Ganser, H. Döhner, R. F. Schlenk
• E-Jahr: 2017
• Jahr: 26 May 2017
• Umfang: 8 S.
• Fussnoten: Published online 26 May 2017 ; Gesehen am 14.08.2018
• Titel Quelle: Enthalten in: Blood cancer journal
• Ort Quelle: London [u.a.] : Nature Publishing Group, 2011
• Jahr Quelle: 2017
• Band/Heft Quelle: 7(2017,5) Artikel-Nummer e564, 8 Seiten
• ISSN Quelle: 2044-5385
• DOI: doi:10.1038/bcj.2017.45
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1578855837

Abstract

The aim of this cohort study was to compare a condensed schedule of consolidation therapy with high-dose cytarabine on days 1, 2 and 3 (HDAC-123) with the HDAC schedule given on days 1, 3 and 5 (HDAC-135) as well as to evaluate the prophylactic use of pegfilgrastim after chemotherapy in younger patients with acute myeloid leukemia in first complete remission. One hundred and seventy-six patients were treated with HDAC-135 and 392 patients with HDAC-123 with prophylactic pegfilgrastim at days 10 and 8, respectively, in the AMLSG 07-04 and the German AML Intergroup protocol. Time from start to chemotherapy until hematologic recovery with white blood cells >1.0 G/l and neutrophils >0.5 G/l was in median 4 days shorter in patients receiving HDAC-123 compared with HDAC-135 (P<0.0001, each), and further reduced by 2 days (P<0.0001) by pegfilgrastim. Rates of infections were reduced by HDAC-123 (P<0.0001) and pegfilgrastim (P=0.002). Days in hospital and platelet transfusions were significantly reduced by HDAC-123 compared with HDAC-135. Survival was neither affected by HDAC-123 versus HDAC-135 nor by pegfilgrastim. In conclusion, consolidation therapy with HDAC-123 leads to faster hematologic recovery and less infections, platelet transfusions as well as days in hospital without affecting survival.